Is doubling of serum creatinine a valid clinical ‘hard’ endpoint in clinical nephrology trials?

Is doubling of serum creatinine a valid clinical ‘hard’ endpoint in clinical nephrology trials?

Nephron Clin Pract. 2011;119(3):c195-9; discussion c199

Authors: Lambers Heerspink…

This entry was posted in Nephron Clin Pract and tagged . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *